Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
about
Melanoma: from melanocyte to genetic alterations and clinical optionsResistant mechanisms to BRAF inhibitors in melanomaMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsTargeting the Checkpoint to Kill Cancer CellsThe GIST of targeted therapy for malignant melanomaPathways and therapeutic targets in melanomaCopy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaCyclin D as a therapeutic target in cancerA melanoma molecular disease modelDiscrepant alterations in main candidate genes among multiple primary melanomasResistance to Raf inhibition in cancer.Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.Using genetics and genomics strategies to personalize therapy for cancer: focus on melanomaThe HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsTargeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Dabrafenib and its potential for the treatment of metastatic melanoma.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanomaBRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaROCK1 is a potential combinatorial drug target for BRAF mutant melanomaEpigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomasConstitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition.Mechanisms of resistance to RAF inhibitors in melanomaPIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signalingCyclin alterations in diverse cancers: Outcome and co-amplification network.BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceUsing quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanomaInhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidenceTargeting mutant BRAF in melanoma: current status and future development of combination therapy strategiesThe current state of targeted therapy in melanoma: this time it's personalEmbryonic signaling in melanoma: potential for diagnosis and therapyFisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cellsEctopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine
P2860
Q54581163-630D5CF0-D49B-468A-9E87-4599ABACEC88Q54603178-1B5E238D-3715-4683-9965-88FD4B333916Q54954013-884429DA-BC5A-40C6-A52B-588762272005Q54994187-552E5CD4-629D-436F-9F72-9055C34A9052Q54994256-1B639CD5-EBC4-45C4-97E8-859A7BE3E738Q54994301-2B0FE970-1FDD-4899-B6A3-C71A7FAB86D4Q54994306-0C4A1BF6-4CBE-4766-88B7-4A50996E7951Q54994340-687D11CB-7167-48AD-B5E4-68352C2ADFDAQ54994345-6A496576-0D54-4187-A280-B2D18DA03C58
P1343
Q21284811-08C3958E-395A-40A6-9EC5-2BD89B8DC07BQ26739717-18A0F4E9-0BF9-41FF-84A1-B386E55203E5Q26771192-54BA58FE-811A-44D1-A881-F1909472B54BQ26795735-C1C88A9E-1D2E-4BA9-BA5E-9D97DFA0FA4DQ26795781-A08EF6CD-7875-4021-AD84-05871CFDD417Q26827092-BFE2ED9F-2DFA-44D2-828F-A212C939523EQ26865736-A412EA80-1878-4579-A494-69909007ACD4Q27853202-CE045B0E-611E-4634-AC62-FF6930546914Q28242623-4458FFDD-F816-4B4E-A78D-EAA835C3BA36Q28741507-3AAADDB9-FCDE-4833-B388-7A23EC55E8D5Q30578299-E69A2A60-E71C-4EBC-9F6B-CC082239BE43Q33651779-566574A1-2FBF-41C7-A7AC-063EE0B14FEDQ33830911-22B2EE07-89A7-484D-B8C1-4999B4D02754Q33965328-B6708ABE-113D-4DC7-814F-80ADC67DE6D8Q34165045-9B3B33D0-EB55-432A-A6E6-411FADCC0144Q34222257-2138E960-BED8-4BE6-BCA4-15DC3FE6ACBBQ34307356-802F8141-3C7C-45B1-861C-21D4528CD469Q34646614-840BDF05-8412-43BB-8DBA-06DE995B2B0FQ34662717-4BDEB057-7480-4B6D-AE30-316165474CB5Q34667825-BF06BF74-B838-42F5-BA94-45DA9B3CDE0CQ34761941-CFEEF482-47E6-473B-A58D-3816B23CA1FAQ34786402-936A7D49-812E-4FF4-9911-FDC92DB9202AQ34990555-4AAE7929-1ED1-431A-84C6-99869A4B20B6Q35018167-BE6F52C7-CC58-4511-B2C8-73671A491187Q35025142-111B0543-1A0A-4D6D-8E09-D3FB671D6CF2Q35166950-921E8C2A-177E-4F8A-A6FD-10C988A43080Q35227481-3EEB140A-BA77-407E-B674-B5E82225E705Q35550165-C023C1F0-067D-4CE6-AB34-02DBB57075E9Q35607456-A94AF0CD-47EC-4F90-AB4D-6DE8DAE45713Q35640196-F33B46B0-6745-4165-8C22-E3548A543E64Q35675442-85E498B4-1498-444F-B9C2-8CE00066A67AQ35679353-3B10DDAB-F294-4002-B879-DB7EFC7598FBQ35706499-F5EAD921-21E6-4964-9A9D-A480CAB41B60Q35746524-71214C55-0520-4890-A1E4-492AF809A43CQ35810176-75DFF896-EBAF-455C-A4CE-E6CF2A8441F0Q35859282-F8B6D382-1DF0-4203-A0C6-5961B03258DAQ35878248-1AE88BB5-024F-422D-9E37-BFD4471E852EQ36239253-2048C4EB-9E2B-4168-B064-902C5FA1C806Q36414039-256B90FF-E968-49BF-829B-EEB9D65387D2Q36556350-6A544DD0-23C6-4EAA-989F-C303DDF6808E
P2860
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Increased cyclin D1 expression ...... n BRAF V600E-mutated melanomas
@en
Increased cyclin D1 expression ...... BRAF V600E-mutated melanomas.
@nl
type
label
Increased cyclin D1 expression ...... n BRAF V600E-mutated melanomas
@en
Increased cyclin D1 expression ...... BRAF V600E-mutated melanomas.
@nl
prefLabel
Increased cyclin D1 expression ...... n BRAF V600E-mutated melanomas
@en
Increased cyclin D1 expression ...... BRAF V600E-mutated melanomas.
@nl
P2093
P2860
P4510
P50
P1476
Increased cyclin D1 expression ...... n BRAF V600E-mutated melanomas
@en
P2093
Alastair J King
Brijal Desai
David E Elder
Johan Hansson
Maurizia Dalla Palma
Mercedes Lioni
Patricia Van Belle
Suzanne Egyhazi
P2860
P304
P356
10.1158/1535-7163.MCT-08-0431
P577
2008-09-01T00:00:00Z